Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice
AUTOR(ES)
Santarem, Ana Angélica Amorim, Greggianin, Gabriel Frizon, Debastiani, Rafaela Garcia, Ribeiro, Jefferson Bruno Pereira, Polli, Demerson Andre, Sampaio, Raimunda Nonata Ribeiro
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2014-08
RESUMO
Introduction The treatment of leishmaniasis ischallenging, given the difficulties in drug administration and resistance. Therefore, we chose to test the efficacy of miltefosine combined with pentoxifylline. Methods Twenty-seven isogenic C57Bl/6 mice were infected with Leishmania (Leishmania) amazonensis, and equally divided into three groups: miltefosine (200mg/kg/day), miltefosine (200mg/kg/day) with pentoxifylline (8mg/kg/day), and untreated. Response to treatment was evaluated using paw diameter and parasitological criteria. Results The number of viable Leishmania reduced significantly within the miltefosine-pentoxifylline group (p < 0.05). Conclusions There is hope that a viable treatment exists for Leishmania infection.
Documentos Relacionados
- Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.
- Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice.
- Cytokine regulation of murine leishmaniasis: interleukin 4 is not sufficient to mediate progressive disease in resistant C57BL/6 mice.
- Effect of age on susceptibility to Salmonella Typhimurium infection in C57BL/6 mice
- Long-term treatment with 3,4-methylenedioxymethamphetamine caused retina damage in C57BL/6 mice